TCBPW Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . TC BioPharm plc
TCBPW Stock  USD 0.02  0  24.67%   
TC BioPharm financial statements provide useful quarterly and yearly information to potential TC BioPharm plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on TC BioPharm financial statements helps investors assess TC BioPharm's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TC BioPharm's valuation are summarized below:
Quarterly Earnings Growth
(0.87)
Revenue
2.9 M
Earnings Share
(0.75)
Revenue Per Share
29.639
There are over one hundred nineteen available fundamental measures for TC BioPharm, which can be analyzed over time and compared to other ratios. All traders should should double-check TC BioPharm's latest fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 731.5 K in 2024. Enterprise Value is likely to drop to about 103.1 K in 2024

TC BioPharm Total Revenue

0.0

Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 78.9 K, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.3. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

TC BioPharm Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10 M8.9 M9.8 M
Slightly volatile
Short and Long Term Debt Total1.7 M1.8 M3.9 M
Very volatile
Other Current Liabilities2.3 M2.5 M2.2 M
Slightly volatile
Total Current Liabilities9.4 M4.8 M5.8 M
Slightly volatile
Property Plant And Equipment Net3.2 M2.6 M4.9 M
Slightly volatile
Accounts Payable1.2 M1.8 M817.5 K
Slightly volatile
Cash2.3 M2.5 M1.4 M
Slightly volatile
Non Current Assets Total3.6 M3.2 M5.3 M
Slightly volatile
Cash And Short Term Investments2.3 M2.5 M1.4 M
Slightly volatile
Net Receivables1.4 M1.2 M2.5 M
Slightly volatile
Common Stock Shares Outstanding32.4 K30.9 K16.7 K
Very volatile
Liabilities And Stockholders Equity10 M8.9 M9.8 M
Slightly volatile
Non Current Liabilities Total1.4 M1.5 M6.9 M
Slightly volatile
Capital Lease Obligations2.1 M1.8 M3.1 M
Slightly volatile
Other Current Assets4.3 M4.1 M2.8 M
Pretty Stable
Total Liabilities10.4 M6.2 M12.6 M
Very volatile
Property Plant And Equipment Gross5.4 M6.8 M6.8 M
Slightly volatile
Total Current Assets5.2 M5.7 M4.4 M
Slightly volatile
Capital Stock2 K2.1 K1.3 M
Slightly volatile
Short Term Debt290.1 K305.3 K915.9 K
Pretty Stable
Intangible Assets523.9 K615.2 K377.1 K
Slightly volatile
Common Stock2 K2.1 K1.2 M
Slightly volatile
Short and Long Term Debt558.7 K588.1 K5.6 M
Slightly volatile

TC BioPharm Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.9 K2 K15.1 K
Slightly volatile
Depreciation And Amortization638 K630.1 K851.1 K
Slightly volatile
Interest Expense78.9 K83 K893.3 K
Slightly volatile
Selling General Administrative5.1 M6.5 M3.7 M
Slightly volatile
Gross Profit3.1 M4.4 M3.3 M
Pretty Stable
Other Operating Expenses6.2 M6.9 M9.1 M
Slightly volatile
Research Development5.9 M7.8 M8 M
Slightly volatile
Total Operating Expenses6.2 M6.9 M9.1 M
Slightly volatile
Reconciled Depreciation736.6 K633 K898.7 K
Pretty Stable
Selling And Marketing Expenses321.9 K362.1 K394.3 K
Slightly volatile

TC BioPharm Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5 M4.8 M5.3 M
Slightly volatile
Depreciation732.8 K633 K896.9 K
Pretty Stable
Capital Expenditures104.8 K110.4 K1.5 M
Slightly volatile
Issuance Of Capital Stock3.3 M4.2 M3.1 M
Very volatile
Total Cash From Financing Activities8.9 M8.5 M5.3 M
Slightly volatile
End Period Cash Flow2.3 M2.5 M1.4 M
Slightly volatile
Change To Inventory2.3 M2.5 M2.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.620.658.0279
Slightly volatile
Days Sales Outstanding9.1810.3311.2471
Slightly volatile
Average Payables836.1 K1.4 M756.6 K
Slightly volatile
Stock Based Compensation To Revenue0.250.260.2627
Slightly volatile
Capex To Depreciation0.170.17431.5369
Slightly volatile
Sales General And Administrative To Revenue1.141.951.1162
Slightly volatile
Research And Ddevelopement To Revenue3.012.272.5919
Pretty Stable
Capex To Revenue0.06840.0720.4096
Slightly volatile
Cash Per Share75.7379.7167520
Very volatile
Income Quality2.51.78521.8705
Slightly volatile
Intangibles To Total Assets0.04260.06890.0387
Slightly volatile
Current Ratio0.611.20.9469
Slightly volatile
Receivables Turnover25.4428.6231.1672
Slightly volatile
Graham Number5816129.8 K
Very volatile
Capex Per Share3.393.5722721
Slightly volatile
Revenue Per Share1.4 K1.3 K1.6 K
Slightly volatile
Interest Debt Per Share46.048.4214607
Slightly volatile
Debt To Assets0.160.16750.7043
Slightly volatile
Ebt Per Ebit0.470.49130.9742
Slightly volatile
Long Term Debt To Capitalization0.290.320.3507
Slightly volatile
Quick Ratio0.611.20.9469
Slightly volatile
Net Income Per E B T0.860.84440.8446
Slightly volatile
Cash Ratio0.540.51840.2867
Slightly volatile
Days Of Sales Outstanding9.1810.3311.2471
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.01051.2154
Slightly volatile
Fixed Asset Turnover0.551.050.6558
Slightly volatile
Debt Ratio0.160.16750.7043
Slightly volatile
Price Sales Ratio0.620.658.0279
Slightly volatile
Asset Turnover0.330.390.3306
Pretty Stable

TC BioPharm Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap731.5 K770 K24.4 M
Slightly volatile

TCBPW Fundamental Market Drivers

Cash And Short Term Investments2.5 M

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-305.3 K-290.1 K
Stock Based Compensation To Revenue 0.26  0.25 
Sales General And Administrative To Revenue 1.95  1.14 
Research And Ddevelopement To Revenue 2.27  3.01 
Capex To Revenue 0.07  0.07 
Revenue Per Share1.3 K1.4 K
Ebit Per Revenue(3.61)(3.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY